Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Linda Diggle a Oxford Vaccine
Group, University Department of Paediatrics, John Radcliffe Hospital,
Oxford OX3 9DU, b ICRF/NHS Centre for Statistics in Medicine, Institute of
Health Sciences, University of Oxford, Oxford OX3 7LF
Correspondence to:
L Diggle linda.diggle{at}paediatrics.oxford.ac.uk
Objective:
To compare rates of local reactions
associated with two needle sizes used to administer routine
immunisations to infants.
Design:
Randomised controlled trial.
Setting:
Routine immunisation clinics in eight general practices in Buckinghamshire.
Participants:
Healthy infants attending for third
primary immunisation due at 16 weeks of age: 119 infants were
recruited, and 110 diary cards were analysed.
Interventions:
Immunisation with 25 gauge, 16 mm,
orange hub needle or 23 gauge, 25 mm, blue hub needle.
Main outcome measures:
Parental recordings of redness,
swelling, and tenderness for three days after immunisation.
Results:
Rate of redness with the longer needle was initially two thirds the rate with the smaller needle (relative risk
0.66 (95% confidence interval 0.45 to 0.99), P=0.04), and by the third
day this had decreased to a seventh (relative risk 0.13 (0.03 to 0.56),
P=0.0006). Rate of swelling with the longer needle was initially about
a third that with the smaller needle (relative risk 0.39 (0.23 to
0.67), P=0.0002), and this difference remained for all three days.
Rates of tenderness were also lower with the longer needle throughout
follow up, but not significantly (relative risk 0.60 (0.29 to 1.25),
P=0.17).
Conclusions:
Use of 25 mm needles significantly
reduced rates of local reaction to routine infant immunisation. On
average, for every five infants vaccinated, use of the longer needle
instead of the shorter needle would prevent one infant from
experiencing any local reaction. Vaccine manufacturers should review
their policy of supplying the shorter needle in vaccine packs.
Read all Rapid Responses